Cybin (CYBN) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

CYBN Cybin

Watchlist

9.5600
-0.4700-4.69%

Close Jan 8 16:00 ET

9.4000
-0.1600-1.67%

Post 20:01 ET

191.12MMarket Cap-1.61P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Businesswire17:00 ET
Express News | Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including Cyb003 12-Month Efficacy Results
ReutersDec 10, 2024 07:30 ET
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
BusinesswireDec 10, 2024 07:30 ET
Facet Life Sciences Named Regulatory Partner for Cybin's Neuropsychiatry Therapeutics Development Pipeline
PR NewswireDec 4, 2024 14:00 ET
Cybin to Discuss Breakthrough Treatments at Fireside Chat
TipRanksDec 4, 2024 08:09 ET
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
BusinesswireDec 4, 2024 07:30 ET

Comments

Jaguar8

Dec 10, 2024 06:44

NEWS

$Cybin (CYBN.US)$
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Tuesday, 10th December at 7:30 am
- Poster presentations highlight clinical data across Cybin's CYB003 deuterated psilocin and DMT programs -
Cybin Inc. (NYSE: CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new...

Trytosaveabit

Dec 4, 2024 13:05

Update! Cybin gettin serious!

$Cybin (CYBN.US)$PR Newswire· 2 mins ago
PHOENIXVILLE, Pa., Dec. 4, 2024 /PRNewswire/ -- Facet Life Sciences, a leader in US regulatory strategy and product development solutions for the life sciences industry, has been named as the US regulatory partner for Cybin Inc. ("Cybin"), a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative treatment options to address the large unmet need for people ...

Mr Trecherous

Nov 25, 2024 20:06

Get Healthy 💪🏼 🥑 🥥 🍄 🐮

$Trump Media & Technology (DJT.US)$ $Pfizer (PFE.US)$ $McDonald's (MCD.US)$ $Tesla (TSLA.US)$ $AMC Entertainment (AMC.US)$ $Cybin (CYBN.US)$

Moo Humor

EZ_money

Nov 21, 2024 10:30

$Cybin (CYBN.US)$ buying more now 🖕

EZ_money

Nov 19, 2024 07:44

$Cybin (CYBN.US)$👀 more news out on trials 100% effectiveness so far on the therapy drug for treating depression
CCORF Maintains Cybin(CYBN.US) With Buy Rating, Maintains Target Price $86
trading under 12 now seems like something is in the works.
$Vertex Pharmaceuticals (VRTX.US)$ $Astera Labs (ALAB.US)$ $Emergent BioSolutions (EBS.US)$

Heat List

Overall

No Data